SRC and breast carcinoma: YAP levels have been identified as a biomarker of Dasatinib sensitivity in breast cancer [48] and, in particular, basal-type triple negative breast cancer (TNBC) cells, which have highly activated Src and YAP, are more sensitive to Dasatinib treatment [46, 38].